NextPoint Networks

NextPoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision immuno-oncology therapeutics. The company focuses on the HHLA2/KIR3DL3 pathway, a novel immune checkpoint axis distinct from the PD-1/L1 pathway, which is highly expressed in various solid tumors. Their lead programs include NPX267, a monoclonal antibody targeting the inhibitory receptor KIR3DL3, and NPX883, which targets the HHLA2 ligand. By leveraging deep expertise in the B7 family of co-stimulatory and co-inhibitory molecules, NextPoint aims to provide effective treatments for patients whose cancers do not respond to current checkpoint inhibitors.